News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Are Impatient Investors Destroying Pharma R&D?


4/28/2014 6:23:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

You’d be hard pressed to find a starker assessment of the current stage of biopharma than the viewpoint offered by William Ackman’s Pershing Square hedge fund, filed in support of their effort to partner with Valeant to acquire Allergan.

First, Ackman notes, as medium term (“our target holding period for our active investments is generally four to six years”) value investors, they’ve historically avoided pharmaceutical companies, preferring instead to invest in businesses with durable products (i.e. not affected by patent expirations) offering “predictable financial results” and “superior long-term growth in free cash flow per share.” Representative holdings they cite include P&G, Burger King, and Kraft.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES